Skip to main navigation Skip to search Skip to main content

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

  • James R. Berenson
  • , Jeffrey Matous
  • , Regina A. Swift
  • , Russell Mapes
  • , Blake Morrison
  • , Howard S. Yeh
  • Institute for Myeloma and Bone Cancer Research and Oncotherapeutics Inc, West Hollywood, CA 90069, USA. [email protected]

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalClinical Cancer Research
Volume13
Issue number6
DOIs
StatePublished - Mar 15 2007

Disciplines

  • Medicine and Health Sciences
  • Gastroenterology
  • Surgery
  • Survival Analysis
  • Internal Medicine

Cite this